JP Morgan Chase
INKT icon

JP Morgan Chase’s MiNK Therapeutics INKT Stock Holding History

JP Morgan Chase’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95 Hold
9
– – ﹤0.01% 7315
2025
Q4 		$100 Hold
9
– – ﹤0.01% 7213
2025
Q3 		$126 Sell
9
-3
-25% -$48 ﹤0.01% 7151
2025
Q2 		$89 Sell
12
-18
-60% -$135 ﹤0.01% 6855
2025
Q1 		$259 Sell
30
-3
-9% -$27 ﹤0.01% 6769
2024
Q4 		$227 Buy
33
+20
+154% +$136 ﹤0.01% 6899
2024
Q3 		$97 Buy
13
+2
+18% +$17 ﹤0.01% 7007
2024
Q2 		$102 Hold
11
– – ﹤0.01% 6887
2024
Q1 		$97 Hold
11
– – ﹤0.01% 6907
2023
Q4 		$115 Hold
11
– – ﹤0.01% 7108
2023
Q3 		$125 Hold
11
– – ﹤0.01% 6889
2023
Q2 		$225 Buy
+11
New +$220 ﹤0.01% 6622
2022
Q3 		– Sell
-25
Closed – – 6644
2022
Q2 		$0 Sell
25
-69
-73% -$1.3K ﹤0.01% 6666
2022
Q1 		$2K Buy
+94
New +$2.82K ﹤0.01% 6422

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase's INKT Position: Q1 2026 in Review

JP Morgan Chase held its MiNK Therapeutics (INKT) position steady in Q1 2026 at 9 shares worth $95. The position accounts for ﹤0.01% of the portfolio, ranked #7315.

JP Morgan Chase first reported a position in INKT in Q1 2022 and has held it in 14 quarters since. The position peaked at $2K in Q1 2022. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • JP Morgan Chase held 9 shares of MiNK Therapeutics worth $95 as of Q1 2026.
  • JP Morgan Chase left its MiNK Therapeutics share count unchanged in Q1 2026.
  • MiNK Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7315 holding.
  • JP Morgan Chase first reported a position in MiNK Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • JP Morgan Chase's MiNK Therapeutics position peaked at $2K in Q1 2022.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.